C-reactive protein: Difference between revisions
imported>Howard C. Berkowitz m (→Diagnostic use) |
imported>Howard C. Berkowitz No edit summary |
||
| Line 8: | Line 8: | ||
| date =Spring 2002 | | date =Spring 2002 | ||
| Pages=13-16 | | Pages=13-16 | ||
| C-Reactive Protein and Erythrocyte Sedimentation Rate in Orthopaedics | | title = C-Reactive Protein and Erythrocyte Sedimentation Rate in Orthopaedics | ||
| author = Husain TM, Kim DH | | author = Husain TM, Kim DH | ||
| journal = University of Pennsylvania Orthopedic Journal | | journal = University of Pennsylvania Orthopedic Journal | ||
|url=}}</ref> | |url=http://www.uphs.upenn.edu/ortho/oj/2002/html/oj15sp02p13.html}}</ref> | ||
Elevation above the patient's baseline in to the accuracy of the predictive power of lipid meassurements in apparently health people. They are also predictive of peripheral vacular disease, supporting the theory that chronic inflammation precedes [[atherosclerosis]]. The test needs more standardization amon laboratories befor in can be recommended routinely. There is early evidence exists that risk factor modification, particularly the use of [[aspirin]] and the | Elevation above the patient's baseline in to the accuracy of the predictive power of lipid meassurements in apparently health people. They are also predictive of peripheral vacular disease, supporting the theory that chronic inflammation precedes [[atherosclerosis]]. The test needs more standardization amon laboratories befor in can be recommended routinely. There is early evidence exists that risk factor modification, particularly the use of [[aspirin]] and the [[hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors]] (i.e., statins, may reduce plaque inflammation.<ref name=EM-CR{>{{citation | ||
| journal = eMedicine | | journal = eMedicine | ||
| title =Atherosclerosis | | title =Atherosclerosis | ||
Revision as of 21:38, 18 October 2008
Template:TOC-right C-reactive protein is one of the circulating blood proteins that help the host defense system begin immune defense by phagocytosis performed my macrophage. Its opsonization of target cells is much less precise than from immunoglobulin generated by B-lympocytes for T8 lymphocytes. When activated, it binds, with the antigen, to a surface receptor on macrophages and opsonize the threatening cells.
Diagnostic use
Along with the erythrocyte sedimentation rate, when laboratory results are elevated, the clinician has warning an an acute inflammatory disorder exists.[1]
Elevation above the patient's baseline in to the accuracy of the predictive power of lipid meassurements in apparently health people. They are also predictive of peripheral vacular disease, supporting the theory that chronic inflammation precedes atherosclerosis. The test needs more standardization amon laboratories befor in can be recommended routinely. There is early evidence exists that risk factor modification, particularly the use of aspirin and the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (i.e., statins, may reduce plaque inflammation.[2] C-reactive protein is a more reliable marker of inlammatory disease than is the electrolyte sedimentation rate in a vasculitis such as giant cell arteritis, also called temporal arteritis; cranial arteritis; or Horton's disease [3] or Microscopic polyangiitis[4]
The presence, in high-sensitivity CRP analysis, shows a predisposition to atherosclerotic blood vessel disease.[5]
References
- ↑ Husain TM, Kim DH (Spring 2002), "C-Reactive Protein and Erythrocyte Sedimentation Rate in Orthopaedics", University of Pennsylvania Orthopedic Journal
- ↑ F Brian Boudi, Chowdhury H Ahsan, James L Orford, Andrew P Selwyn (Aug 10, 2006), "Atherosclerosis", eMedicine
- ↑ Giant cell arteritis, Merck Manual for Healthcare Professionals
- ↑ Microscoping polyangiitis, Merck Manual for Healthcare Professionals
- ↑ Flores-Alfaro E, Parra-Rojas I, Salgado-Bernabé AB, Chávez-Maldonado JP,Salazar-Martinez E. (July 0008), "Cardiovascular risk evaluated by C-reactive protein levels in diabetic and obese Mexican subjects.", Circ J. 72(7): 1170-4.|